Is KLOW approved as a medicine, and where?

The regulatory review of KLOW is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is KLOW studied for?

Research has examined Component-level anti-inflammatory and tissue-repair research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.

Does KLOW have human clinical trials?

The evidence review of KLOW is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Peptide Blends

KLOW

Name: KLOW
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

KLOW blend; KLOW peptide; KLOW 80

2 min read · Updated October 7, 2026 · 11 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

KLOW = GLOW + KPV as a vendor blend, not an upgraded single drug. No controlled combination data. Any anti-inflammatory "upgrade" from adding KPV is a hypothesis from component literature, not a measured blend result. No dose or protocol is established.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Four-peptide trade blend: GHK-Cu + KPV + BPC-157 + TB-500 — not a covalent molecule
Typical labelled total ~80 mg (often 50 + 10 + 10 + 10 mg); that is total label mass, not 80 mg of each peptide
No controlled study of the four components together was identified (2026-10-07 dossier)
KPV has preclinical anti-inflammatory findings; that does not prove a KLOW blend benefit
Same TB-500 vs full thymosin β4 identity trap as GLOW

↓ Read the full referenced entry below

KLOW is a commercial name for a four-peptide lyophilized mixture that adds KPV to the GLOW core (GHK-Cu + BPC-157 + TB-500). It is not a new molecule. No controlled study of the four-way combination was identified; evidence is component-wise, with KPV limited to preclinical work.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents6

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). It is visible in the wiki but noindexed. Editorial lane: scope-review-blend.

No controlled combination data

In the reviewed 2026-10-07 dossier, no controlled study of GHK-Cu + KPV + BPC-157 + TB-500 as a fixed blend was identified. Any claimed anti-inflammatory advantage from adding KPV to a GLOW-style core is a hypothesis from component literature, not a measured blend result. No dose or protocol is published here.

Section 1 of 6GLOW vs KLOW

GLOW vs KLOW

	GLOW	KLOW
Peptide count	3	4
Core	GHK-Cu + BPC-157 + TB-500	Same core
Extra	—	KPV (Lys-Pro-Val)
Typical labelled total	~70 mg (50+10+10)	~80 mg (50+10+10+10)
Molecular status	Mixture, not a new molecule	Mixture, not a new molecule
Controlled combination data	None identified	None identified

KLOW is not an "improved GLOW molecule". It is the GLOW core plus a fourth named peptide in the same vial.

Section 2 of 6Typical labelled composition

Typical labelled composition

Component	Typical labelled amount	Monograph
GHK-Cu	~50 mg	See component page
KPV	~10 mg	Preclinical anti-inflammatory tripeptide
BPC-157	~10 mg	See component page
TB-500	~10 mg	Fragment vs thymosin beta-4 caveat

80 mg on a label is usually the sum, not 80 mg of each peptide. Lot COAs may diverge from the label; "TB-500" identity remains batch-dependent (same trap as GLOW).

Section 3 of 6KPV — the component that distinguishes KLOW

KPV — the component that distinguishes KLOW

KPV is α-MSH(11–13) (Lys-Pro-Val; ~342.4 g/mol). Published work cited on the KPV monograph and re-checked for this dossier is preclinical (e.g. PepT1-related intestinal inflammation models, α-MSH-core comparisons, nanoparticle colitis delivery, rabbit corneal topical work). No human RCT or approved indication for KPV was identified in the reviewed material.

A PubMed-style combination query (KPV AND BPC-157 OR GHK-Cu OR TB-500) did not yield a KLOW blend study.

PCAC July 2026 included separate questions on KPV free base / acetate as bulk drug substances — again for the substance, not for KLOW.

Section 4 of 6Claims vs evidence

Claims vs evidence

Claim	Assessment
KLOW = GLOW + KPV	Supported as a trade definition
KPV makes the blend an "anti-inflammatory upgrade"	Not verified for the blend; KPV has preclinical anti-inflammatory findings alone
80 mg = 80 mg of each peptide	False — typically total label mass
Clinical injection protocol	Reject
Approved drug blend	False

Section 5 of 6Related pages

GLOW, The Wolverine Blend
GHK-Cu, KPV, BPC-157, TB-500

Section 6 of 6What this page intentionally omits

What this page intentionally omits

Stack protocols, reconstitution schedules, or injection schemes
Synergy percentages
Medical use advice

References11

References

1.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Dalmasso G, et al., Gastroenterology / related, 2008. source
2.
α-MSH and C-terminal KPV in inflammation models — Getting SJ, et al., 2003. source
3.
Nanoparticle-mediated delivery of KPV in colitis models — Xiao B, et al., Molecular Therapy, 2017. source
4.
Topical KPV and corneal epithelial healing (rabbit) — 2006. source
5.
KPV and fine-dust keratinocyte inflammation (preclinical) — 2025. source
6.
FDA PCAC Final Questions — July 23–24 2026 (includes separate KPV votes) — U.S. Food and Drug Administration, 2026. source
7.
PeptideInfo — KPV source
8.
PeptideInfo — GLOW source
9.
PeptideInfo — GHK-Cu source
10.
PeptideInfo — BPC-157 source
11.
PeptideInfo — TB-500 source

Frequently asked questions4

Frequently asked questions

What is KLOW?: KLOW is a commercial name for a four-peptide lyophilized mixture that adds KPV to the GLOW core (GHK-Cu + BPC-157 + TB-500). It is not a new molecule. No controlled study of the four-way combination was identified; evidence is component-wise, with KPV limited to preclinical work.
Is KLOW approved as a medicine, and where?: The regulatory review of KLOW is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is KLOW studied for?: Research has examined Component-level anti-inflammatory and tissue-repair research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.
Does KLOW have human clinical trials?: The evidence review of KLOW is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of KLOW is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.